- VRTX -1.37%
Vertex’s blockbuster-in-waiting painkiller suzetrigine set for FDA review next year
Yahoo Finance · 20 hours ago
Search results
Vertex Pharmaceuticals invests in scientific innovation to create transformative medicines for people with serious diseases.
- 495.72Add to watchlist-6.88 (-1.37%)At close:4:00 PM EDTWed. Jul 31, 2024493.13 -2.59 (-0.52%)Pre mkt:7:51 AM EDTThu. Aug 1, 2024Nasdaq Real Time Price (USD) · Pre-Market Time
- Open507.04High507.80Low495.30
- Mkt Cap127.92BP/E (TTM)32.17Div & YieldN/A & N/A
- Prev. Close502.6052 Wk. Low340.2052 Wk. High507.80
What analysts are sayingTop storiesRelated stocks
Vertex Pharmaceuticals Incorporated is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry.
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF).
Vertex Pharmaceuticals strikes at the core of serious diseases to change people's lives – learn about our mission, values and recognition.
2 days ago · Vertex Pharmaceuticals Incorporated Investors: InvestorInfo@vrtx.com Susie Lisa, CFA: +1 617-341-6108 or Miroslava Minkova: +1 617-341-6135 Media: mediainfo@vrtx.com or International: +44 20 3204 5275 or U.S.: 617-341-6992 or Heather Nichols: +1 617-839-3607 Source: Vertex Pharmaceuticals Incorporated
The Investor Relations website contains information about Vertex Pharmaceuticals's business for stockholders, potential investors, and financial analysts.
Vertex Announces Positive Results From Ongoing Phase 1/2 Study of VX-880 for the Treatment of Type 1 Diabetes Presented at the American Diabetes Association 84th Scientific Sessions. Read More.
Aug 10, 2014 · Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases. We discovered and...
May 30, 2024 · A new era of personalized medicine began last fall when the U.S. and other countries gave the first-ever approvals to a treatment based on CRISPR gene editing: Casgevy, developed by Vertex and...
Jul 25, 2024 · Vertex Pharmaceuticals (VRTX 0.58%) is trading near a record high after climbing about 20% so far this year, and delivering a triple-digit gain over three years. So, you may be a bit hesitant ...
